Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
filingDate |
2008-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2017-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-101701686-B1 |
titleOfInvention |
Novel antibodies inhibiting c-Met dimerization, and uses thereof |
abstract |
The present invention relates to novel antibodies capable of specifically binding to human c-Met receptors and / or new antibodies capable of specifically inhibiting the tyrosine kinase activity of said receptors, particularly chimeric ) And monoclonal antibodies of human origin and amino acid and nucleic acid sequences encoding these antibodies. More specifically, antibodies according to the present invention may inhibit c-Met dimerization. The present invention likewise likewise relates to uses of these antibodies as medicaments for the prophylactic and / or therapeutic treatment of all pathologies associated with the cancer or the overexpression of said receptor, And diagnostic methods or kits for diagnosing diseases associated with expression. The present invention is based on the discovery that other antibodies and / or chemical compounds and / or anti-cancer agents or toxins (" anti-cancer agents ") against ultrastructural growth factors or other growth factors involved in metastasis products and / or compositions of such antibodies in combination with drugs conjugated to toxins, and their use in the prevention and / or treatment of certain cancers. |
priorityDate |
2007-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |